Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China

CompletedOBSERVATIONAL
Enrollment

2,005

Participants

Timeline

Start Date

April 22, 2020

Primary Completion Date

June 25, 2024

Study Completion Date

June 25, 2024

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
OTHER

Prospective observational cohort study

Prospective observational cohort study

Trial Locations (41)

361004

GSK Investigational Site, Xiamen

510030

GSK Investigational Site, Qingyuan

510080

GSK Investigational Site, Guangzhou

510120

GSK Investigational Site, Guangzhou

510150

GSK Investigational Site, Guangzhou

510220

GSK Investigational Site, Guangzhou

510260

GSK Investigational Site, Guangzhou

510515

GSK Investigational Site, Guangzhou

510700

GSK Investigational Site, Guangzhou

511400

GSK Investigational Site, Guangzhou

512026

GSK Investigational Site, Shaoguan

512600

GSK Investigational Site, Wengyuan

514700

GSK Investigational Site, Meizhou

515031

GSK Investigational Site, Shantou

515041

GSK Investigational Site, Shantou

515300

GSK Investigational Site, Jieyang

516000

GSK Investigational Site, Huizhou

516001

GSK Investigational Site, Huizhou

517199

GSK Investigational Site, Heyuan

517300

GSK Investigational Site, Heyuan

518005

GSK Investigational Site, Shenzhen

518020

GSK Investigational Site, Shenzhen

518100

GSK Investigational Site, Shenzhen

518101

GSK Investigational Site, Shenzhen

518104

GSK Investigational Site, Shenzhen

518116

GSK Investigational Site, Shenzhen

519000

GSK Investigational Site, Zhuhai

522000

GSK Investigational Site, Jieyang

523059

GSK Investigational Site, Dongguan

523326

GSK Investigational Site, Dongguan

524001

GSK Investigational Site, Zhanjiang

526400

GSK Investigational Site, Zhaoqing

527400

GSK Investigational Site, Yunfu

528000

GSK Investigational Site, Foshan

528041

GSK Investigational Site, Foshan

528200

GSK Investigational Site, Foshan

528300

GSK Investigational Site, Shunde

528400

GSK Investigational Site, Zhangshan

528415

GSK Investigational Site, Zhangshan

529000

GSK Investigational Site, Jiangmen

529700

GSK Investigational Site, Jiangmen

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Guangzhou Institute of Respiratory Health (GIRH)

UNKNOWN

lead

GlaxoSmithKline

INDUSTRY

NCT04853225 - Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China | Biotech Hunter | Biotech Hunter